Treatment Comparison
Confidence in Knowing Your Status
For localized prostate cancer removing the prostate through radical prostatectomy has traditionally been considered the definitive way to treat the cancer.1
Removing the cancerous prostate lets your doctor see the extentand nature of the cancer. This step can be critical: In clinicalstudies,up to 35% of tumors are undergraded; in other words, theyare more aggressive than the pre-surgery assessment and biopsyresults indicated.2
Margin status refers to whether or not there is cancerpresent at the very edge (the margin) of the removed prostategland. A negative margin means that all edges of the prostate arefree from cancer cells. A negative margin is a good indicator thatall of the cancer has been removed.
This guide was designed to provide patients with information on the surgical treatment of prostate cancer, which can be performed in a very precise, minimally invasive manner using the da Vinci® Surgical System.
Surgery: Preserving Your Options
Choosing surgery over radiation can make it easier for your doctor to detect a cancer recurrence, through careful PSA* monitoring, after a radical prostatectomy than after radiation therapy.3It can also help preserve your radiation treatment options if yourcancer returns. After radiation therapy, there may be damage tothe tissue surrounding the prostate. If you have tissue damage,nerve-sparing surgery may no longer be an option should yourcancer recur. However, radiation usually remains an option forpatients who have had surgery to treat their prostate cancer.4
*PSA= Prostate-Specific Antigen, a protein that may indicate the presence of cancer.
1Prostate cancer clinical guideline update panel. Guideline for the management of clinically localized prostate cancer: 2007 update. Linthicum (MD): American Urological Association Education and Research, Inc. 2007; 82.
2King CR, Patterns of prostate cancer biopsy grading: trends and clinical implications. Int J. Cancer (Radiat. Oncol. Invest.) 2000; 90,305-311.
3Di Blasio, C. J., A. C. Rhee, et al. Predicting clinical end points: treatment nomograms in prostate cancer. Semin Oncol. 2005; 30(5):567-86.
4Carlucci JR, Nabizada-Pace F, Samadi DB. Organ-confined prostate cancer and the emergence of robotic prostatectomy: What primary care physicians and geriatricians need to know. Geriatrics. 2009; 64(2):8-14.
PN 873905 Rev A 02/12






